Cargando…

The distinctive nature of adenocarcinoma of the lung

In recent years, many personalized treatments have been developed for NSCLC (non-small-cell lung cancer) patients. Among these, gefitinib, erlotinib, and afatinib are selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for patients with EGFR gene mutations, while crizotinib...

Descripción completa

Detalles Bibliográficos
Autor principal:	Roviello, Giandomenico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562731/ https://www.ncbi.nlm.nih.gov/pubmed/26366094 http://dx.doi.org/10.2147/OTT.S89225

Ejemplares similares

Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors
por: Catalano, Martina, et al.
Publicado: (2022)

Advances in anti-BRAF therapies for lung cancer
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Association between Low-Grade Chemotherapy-Induced Peripheral Neuropathy (CINP) and Survival in Patients with Metastatic Adenocarcinoma of the Pancreas
por: Catalano, Martina, et al.
Publicado: (2021)

MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy
por: Rodriquenz, Maria Grazia, et al.
Publicado: (2020)

Gut Microbiota Modulation in the Context of Immune-Related Aspects of Lactobacillus spp. and Bifidobacterium spp. in Gastrointestinal Cancers
por: Kaźmierczak-Siedlecka, Karolina, et al.
Publicado: (2021)

Editorial: Microbiota and metabolites in cancer immunotherapy
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Natural and artificial binders of polyriboadenylic acid and their effect on RNA structure
por: Roviello, Giovanni N, et al.
Publicado: (2015)

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Electronic nicotine delivery systems (ENDS): not still ready to put on END
por: Lavacchi, Daniele, et al.
Publicado: (2020)

Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies
por: D’Angelo, Alberto, et al.
Publicado: (2020)

Hyperthermic Intraperitoneal Chemotherapy in the Management of Gastric Cancer: A Narrative Review
por: Mazurek, Marek, et al.
Publicado: (2022)

Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Interdisciplinary insights into the link between gut microbiome and gastric carcinogenesis—what is currently known?
por: Kaźmierczak-Siedlecka, Karolina, et al.
Publicado: (2021)

PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy
por: Sobhani, Navid, et al.
Publicado: (2017)

Androgen receptor splice variant 7 in castration resistant prostate cancer treated with hormonal therapy: what is in the pipeline?
por: Chirra, Martina, et al.
Publicado: (2019)

The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Immune combinations and complete response: a new hope for metastatic renal cell carcinoma
por: Catalano, Martina, et al.
Publicado: (2022)

Methylene Blue—Current Knowledge, Fluorescent Properties, and Its Future Use
por: Cwalinski, Tomasz, et al.
Publicado: (2020)

State-of-the-Art of Monoclonal Antibodies for the Treatment of Gastric Cancer
por: Basile, Debora, et al.
Publicado: (2021)

Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope?
por: Cosso, Federica, et al.
Publicado: (2023)

Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma
por: D’Angelo, Alberto, et al.
Publicado: (2019)

Metachronous primary lung adenocarcinomas harboring distinct KRAS mutations
por: Hu, Yan, et al.
Publicado: (2020)

An Immune-Related Genetic Feature Depicted the Heterogeneous Nature of Lung Adenocarcinoma and Squamous Cell Carcinoma and Their Distinctive Predicted Drug Responses
por: Li, Qiuyuan, et al.
Publicado: (2022)

Numb has distinct function in lung adenocarcinoma and squamous cell carcinoma
por: Kikuchi, Hajime, et al.
Publicado: (2018)

Comprehensive Profiling Reveals Distinct Microenvironment and Metabolism Characterization of Lung Adenocarcinoma
por: Li, Chang, et al.
Publicado: (2021)

A Distinct Glucose Metabolism Signature of Lung Adenocarcinoma With Prognostic Value
por: Li, Ding, et al.
Publicado: (2022)

Distinct immune microenvironment of lung adenocarcinoma in never-smokers from smokers
por: Luo, Wenxin, et al.
Publicado: (2023)

An update on antibody–drug conjugates in urothelial carcinoma: state of the art strategies and what comes next
por: D’Angelo, Alberto, et al.
Publicado: (2022)

Retracted: An Immune-Related Genetic Feature Depicted the Heterogeneous Nature of Lung Adenocarcinoma and Squamous Cell Carcinoma and Their Distinctive Predicted Drug Responses
por: Longevity, Oxidative Medicine and Cellular
Publicado: (2023)

Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Comparison of Anti–Programmed Cell Death Ligand 1 Therapy Combinations vs Sunitinib for Metastatic Renal Cell Carcinoma: A Meta-analysis
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

Hepatoid Adenocarcinoma of the Lung
por: Li, Meihui, et al.
Publicado: (2021)

Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
por: von Eyben, Finn Edler, et al.
Publicado: (2017)

Smoker and non-smoker lung adenocarcinoma is characterized by distinct tumor immune microenvironments
por: Li, Xufan, et al.
Publicado: (2018)

Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
por: Campbell, Joshua D., et al.
Publicado: (2016)

Proteomic analysis enables distinction of early‐ versus advanced‐stage lung adenocarcinomas
por: Kelemen, Olga, et al.
Publicado: (2020)

Distinct Roles of VEGFA and ANGPT2 in Lung Adenocarcinoma and Squamous Cell Carcinoma
por: Qin, Shuang, et al.
Publicado: (2020)

Distinct tumor bacterial microbiome in lung adenocarcinomas manifested as radiological subsolid nodules
por: Ma, Yi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_67nehsf9ahc2if215nimmpe94k